The Endocrine Society

The Healio and Endocrine Today editors have compiled the most read news from the Endocrine Society annual meeting in June.

ATLANTA — Adults with overweight or obesity and nonalcoholic fatty liver disease, or NAFLD, had a significant reduction in liver fat and inflammation with daily subcutaneous growth hormone administration, according to a speaker.

ATLANTA — An ultrasound-based artificial intelligence classifier of thyroid nodules identified benign nodules with sensitivity similar to fine-needle aspiration, according to data presented at ENDO 2022.

ATLANTA — COVID-19 vaccination is not associated with changes in thyroid function or an increased risk for adverse outcomes for people with hypothyroidism, according to data presented at ENDO 2022.

ATLANTA — Adults with growth hormone deficiency have higher health care costs and more comorbidities than those without growth hormone deficiency, according to findings presented at ENDO 2022.

ATLANTA — More than 90% of adults with acromegaly remained responders to oral octreotide 3 years after initiating treatment, according to findings from the MPOWERED open-label extension study presented at ENDO 2022.

ATLANTA — Women with obesity have fewer ovarian follicles that remained static for longer and regressed more slowly compared with those found in women with normal weight, according to findings presented at ENDO 2022.

ATLANTA — Testosterone undecanoate therapy is associated with improved quality of life and reduced symptom severity in men with hypogonadism and type 2 diabetes, according to data presented at ENDO 2022.

ATLANTA — Use of empagliflozin was associated with a nearly 40% reduced risk for nephrolithiasis among people with type 2 diabetes, according to data presented at ENDO 2022.

ATLANTA — Stress related to the COVID-19 pandemic was associated with an increase in subclinical ovulatory disturbances among women without a change in menstrual cycle length, according to a speaker at ENDO 2022.